{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:56:17Z","timestamp":1780505777991,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Correvio Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant for conversion of AF to sinus rhythm in daily practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and Results<\/jats:title>\n                <jats:p>Consenting patients with symptomatic recent-onset AF (&lt;\u20097\u00a0days) treated with IV vernakalant were enrolled and followed up to 24\u00a0h after the last infusion or until discharge, in order to determine the incidence of predefined serious adverse events (SAEs) and other observed SAEs and evaluate the conversion rate within the first 90\u00a0min. Overall, 2009 treatment episodes in 1778 patients were analyzed. The age of patients was 62.3\u2009\u00b1\u200913.0\u00a0years (mean \u00b1 standard deviation). Median AF duration before treatment was 11.1\u00a0h (IQR 5.4\u201327.0\u00a0h). A total of 28 SAEs occurred in 26 patients including 19 predefined SAEs, i.e., sinus arrest (<jats:italic>n<\/jats:italic>\u2009=\u20094, 0.2%), significant bradycardia (<jats:italic>n<\/jats:italic>\u2009=\u200911, 0.5%), significant hypotension (<jats:italic>n<\/jats:italic>\u2009=\u20092, 0.1%), and atrial flutter with 1:1 conduction (<jats:italic>n<\/jats:italic>\u2009=\u20092, 0.1%). There were no cases of sustained ventricular arrhythmias or deaths. All patients who experienced SAEs recovered fully (<jats:italic>n<\/jats:italic>\u2009=\u200925) or with sequelae (<jats:italic>n<\/jats:italic>\u2009=\u20091). Conversion rate to sinus rhythm was 70.2%, within a median of 12\u00a0min (IQR 8.0\u201328.0\u00a0min).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This large multicenter, international observational study confirms the good safety profile and the high effectiveness of vernakalant for the rapid cardioversion of recent-onset AF in daily hospital practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-020-07103-9","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T09:13:19Z","timestamp":1605690799000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-1043","authenticated-orcid":false,"given":"Samuel","family":"L\u00e9vy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tord","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Carbajosa-Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Domanovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"7103_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837\u201347.","journal-title":"Circulation."},{"key":"7103_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"7103_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS; the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Endorsed by the European stroke organization (ESO). Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"7103_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","volume":"62","author":"KE Airaksinen","year":"2013","unstructured":"Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187\u201311926.","journal-title":"J Am Coll Cardiol"},{"key":"7103_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1540-8167.2005.50028.x","volume":"16","author":"D Fedida","year":"2005","unstructured":"Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227\u201338.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"7103_CR6","unstructured":"European Medicines Agency. Summary of product characteristics: Vernakalant. https:\/\/www.ema.europa.eu\/documents\/product-information\/brinavess-epar-product-information_en.pdf. Accessed October 02, 2019."},{"key":"7103_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","volume":"117","author":"D Roy","year":"2008","unstructured":"Roy D, Pratt CM, Torp-Pedersen C, et al. Atrial arrhythmia conversion trial investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518\u201325.","journal-title":"Circulation"},{"key":"7103_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","volume":"2","author":"PR Kowey","year":"2009","unstructured":"Kowey PR, Dorian P, Mitchell LB, et al. Atrial arrhythmia conversion trial I. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"7103_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.amjcard.2010.06.054","volume":"106","author":"CM Pratt","year":"2010","unstructured":"Pratt CM, Roy D, Torp-Pedersen C, et al. Atrial arrhythmia conversion trial investigators. Usefulness of Vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010;106:1277\u201383.","journal-title":"Am J Cardiol"},{"key":"7103_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ahj.2010.02.035","volume":"159","author":"IG Stiell","year":"2010","unstructured":"Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010;159:1095\u2013101.","journal-title":"Am Heart J"},{"key":"7103_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0289-0","volume":"16","author":"GN Beatch","year":"2016","unstructured":"Beatch GN, Mangal B. Safety and efficacy of Vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc Disord. 2016;16:113.","journal-title":"BMC Cardiovasc Disord"},{"key":"7103_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","volume":"57","author":"AJ Camm","year":"2011","unstructured":"Camm AJ, Capucci A, Hohnloser SH, et al. AVRO investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"7103_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FJC.0000000000000445","volume":"69","author":"GN Beatch","year":"2017","unstructured":"Beatch GN, Bhirangi K, Juul-Moller S, Rustige J. Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia-Pacific region: a phase 3 randomized controlled trial. J Cardiovasc Pharmacol. 2017;69:86\u201392.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7103_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/pace.12548","volume":"38","author":"JP Costabel","year":"2015","unstructured":"Costabel JP, Lambardi F, Aragon M, et al. Predictors of conversion of recent-onset atrial fibrillation treated with vernakalant. Pacing Clin Electrophysiol. 2015;38:196\u2013200.","journal-title":"Pacing Clin Electrophysiol"},{"key":"7103_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11845-017-1576-1","volume":"186","author":"P Stoneman","year":"2017","unstructured":"Stoneman P, Gilligan P, Mahon P, Sheahan R. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using Vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge. Ir J Med Sci. 2017;186:903\u20138.","journal-title":"Ir J Med Sci"},{"key":"7103_CR16","first-page":"1330.e1313","volume":"29","author":"D Conde","year":"2013","unstructured":"Conde D, Costabel JP, Aragon M, et al. Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation. Can J Cardiol. 2013;29:1330.e1313.","journal-title":"Can J Cardiol"},{"key":"7103_CR17","first-page":"397","volume":"29","author":"J Carbajosa Dalmau","year":"2017","unstructured":"Carbajosa Dalmau J, Cos\u00edn-Sales J, et al. Vernakalant in hospital emergency practice: safety and effectiveness. Emergencias. 2017;29:397\u2013402.","journal-title":"Emergencias."},{"key":"7103_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/eux161.086","volume":"19","author":"A Simon","year":"2017","unstructured":"Simon A, Niederdoeckl J, Skyllouriotis E, et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. Europace. 2017;19:233\u201340.","journal-title":"Europace."},{"key":"7103_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0735-1097(97)00534-2","volume":"31","author":"PG Danias","year":"1998","unstructured":"Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous cardioversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31:588\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"7103_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA."},{"key":"7103_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/2048872617728558","volume":"8","author":"H Pohjantahti-Maaroos","year":"2019","unstructured":"Pohjantahti-Maaroos H, Hyppola H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J. Intravenous Vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2019;8:114\u201320.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"7103_CR22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/europace\/euz175","volume":"21","author":"WF McIntyre","year":"2019","unstructured":"McIntyre WF, Healey JS, Bhatnagar AK, et al. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21:1159\u201366.","journal-title":"Europace."},{"key":"7103_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10557-012-6374-4","volume":"26","author":"LD Bash","year":"2012","unstructured":"Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by Vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2012;26:167\u201379.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7103_CR24","first-page":"67","volume":"21","author":"I Vogiatzis","year":"2017","unstructured":"Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E. Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. Hippokratia. 2017;21(2):67\u201373.","journal-title":"Hippokratia."},{"key":"7103_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/europace\/eut274","volume":"16","author":"I Savelieva","year":"2014","unstructured":"Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC guidelines. Europace. 2014;16:162\u201373.","journal-title":"Europace."},{"issue":"6","key":"7103_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.annemergmed.2013.06.005","volume":"62","author":"CL Atzema","year":"2013","unstructured":"Atzema CL, Austin PC, Miller E, Chong AS, Yun L, Dorian P. A population-based description of atrial fibrillation in the emergency department, 2002 to 2010. Ann Emergency Med. 2013;62(6):570\u2013577.e7.","journal-title":"Ann Emergency Med"},{"key":"7103_CR27","doi-asserted-by":"crossref","unstructured":"Pluymaekers NAHA, Dudink EAMP, Luermans JGLM et al. RACE 7 ACWAS Investigators. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019; 380(16):1499\u20131508.","DOI":"10.1056\/NEJMoa1900353"},{"issue":"2","key":"7103_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/eupc.2002.0300","volume":"5","author":"S L\u00e9vy","year":"2003","unstructured":"L\u00e9vy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the working group on arrhythmias and the working group on cardiac pacing of the European Society of Cardiology and the north American Society of Pacing and Electrophysiology. Europace. 2003;5(2):119\u201322.","journal-title":"Europace"},{"key":"7103_CR29","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1161\/01.CIR.103.19.2365","volume":"103","author":"KH Humphries","year":"2001","unstructured":"Humphries KH, Kerr CR, Connolly SJ. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2265\u2013370.","journal-title":"Circulation"},{"key":"7103_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/europace\/eun369","volume":"11","author":"M Nabauer","year":"2009","unstructured":"Nabauer M, Gerth A, Limburg T, et al. The registry of German competence network on atrial fibrillation: patient characteristics and initial management. Europace. 2009;11:423\u201343.","journal-title":"Europace"},{"key":"7103_CR31","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1161\/01.CIR.99.23.3028","volume":"99","author":"S L\u00e9vy","year":"1999","unstructured":"L\u00e9vy S, Maarek M, Ph C, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation. 1999;99:3028\u201335.","journal-title":"Circulation"},{"key":"7103_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/CLEP.S47385","volume":"16","author":"M Zoni-Berisso","year":"2014","unstructured":"Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation : European perspective. Clinical Epidemiol. 2014;16:213\u201320 eCollection 2014.","journal-title":"Clinical Epidemiol"},{"key":"7103_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/hrt.29.4.469","volume":"29","author":"B Lown","year":"1967","unstructured":"Lown B. Electrical reversion of cardiac arrhythmias. Brit Heart J. 1967;29:469\u201389.","journal-title":"Brit Heart J"},{"key":"7103_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-5273(03)00107-4","volume":"92","author":"IA Khan","year":"2002","unstructured":"Khan IA. Atrial stunning: basics and clinical considerations. International J Cardiol. 2002;92:113\u201328.","journal-title":"International J Cardiol"},{"key":"7103_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0002-9149(94)90915-6","volume":"74","author":"A Capucci","year":"1994","unstructured":"Capucci A, Boriani G, Botto GL, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 1994;74:503\u20135.","journal-title":"Am J Cardiol"},{"key":"7103_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0002-9149(96)00566-8","volume":"78","author":"PR Kowey","year":"1996","unstructured":"Kowey PR, VanderLugt JT, Luderer JR. Safety and risk\/benefit analysis of ibutilide for acute conversion of atrial fibrillation\/flutter. Am J Cardiol. 1996;78:46\u201352.","journal-title":"Am J Cardiol"},{"key":"7103_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3122\/jabfm.2011.01.080096","volume":"24","author":"M Nair","year":"2011","unstructured":"Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011;24:86\u201392.","journal-title":"J Am Board Fam Med"},{"key":"7103_CR38","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125\u201351.","journal-title":"Circulation."},{"key":"7103_CR39","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm AJ, et al. European heart survey investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J. 2005;26:2422\u201334.","journal-title":"Eur Heart J"},{"key":"7103_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0002-8703(03)00524-6","volume":"147","author":"JY Le Heuzey","year":"2004","unstructured":"Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121\u20136 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14691429.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07103-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-020-07103-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07103-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T06:11:22Z","timestamp":1616652682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-020-07103-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["7103"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07103-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"19 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Professor Levy reports no conflicts of interest. Professor Hartikainen has been an investigator in studies sponsored by AstraZeneca, Biosense Webster, Boehringer Ingelheim, Correvio International S\u00e0rl, Medtronic, and St. Jude Medical. Dr. Ritz is an employee of Correvio International S\u00e0rl, Geneva, Switzerland. Dr. Juhlin has received speaker honoraria from Correvio International S\u00e0rl. Professor Domanovits reports no conflicts of interest. Dr. Carbajosa-Dalmau has received speaker honoraria from Correvio International S\u00e0rl.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}